$CGNT (Cogentix Medical, Inc.)

$CGNT {{ '2016-09-08T12:11:32+0000' | timeago}} • Announcement

$CGNT will convert into common shares all outstanding debt and accrued interest owed to its director Lewis Pell of $29.5MM. Debt owed by $CGNT to Pell will be converted into $CGNT stock at $1.67 immediately before closing the Accelmed deal. The deal also provides that all outstanding warrants to purchase $CGNT stock held by Pell will be cancelled.

$PG {{ '2018-01-23T20:57:54+0000' | timeago}} • Webcast

$PG plans to continue to keep bottom-line growing and to be growing margins through productivity which will both provide fuel for reinvestment and for margin improvement. $PG really doesn't view pricing and promotion as high in terms of its options to grow business. $PG is going to be continuing to invest in business to drive margins.

$PG {{ '2018-01-23T20:52:41+0000' | timeago}} • Webcast

$PG said it will continue its strong track record of cash returned to shareholders. $PG expects to pay nearly $7.5Bil in dividends this year. $PG is lifting FY18 share repurchase outlook from $4-7Bil to $6-8Bil, reflecting strong operating cash flow, continued working capital progress, and the cash benefit enabled by the Tax Act.

$PG {{ '2018-01-23T20:49:54+0000' | timeago}} • Webcast

$PG had already reduced number of agencies nearly 60% from 6,000 to 2,500, saved $750MM in agency and production costs, and improved cash flow by over $400MM additional through 75 day payment terms. In next phase, $PG expects to save another $400MM reducing number of agencies by another 50% and implementing new advertising and media agency models.

$PG {{ '2018-01-23T20:48:49+0000' | timeago}} • Webcast

$PG's core gross margin for 2Q18 declined 80 basis points versus year ago. 150 basis points of productivity savings were more than offset by headwinds of 90 points from higher commodity costs, 70 basis points of mixed impact, 50 basis points from pricing primarily Gillette, and 40 basis points of reinvestment in product and packaging innovation.

$PG {{ '2018-01-23T20:48:35+0000' | timeago}} • Webcast

$PG said commodity prices have continued to move higher as the year has progressed approaching a $350MM after-tax impact versus year ago for FY18. $PG had expected to see higher pulp costs going into the year. These costs have continued to increase beyond initial forecast ranges with strong demand and some recent supply disruption.

$PG {{ '2018-01-23T13:59:12+0000' | timeago}} • Announcement

$PG lifted FY18 core EPS growth outlook to 5-8% from 5-7% versus FY17 core EPS of $3.92. This is to reflect the potential benefit from the Tax Act. GAAP EPS are expected to decrease 30-32% versus FY17 GAAP EPS of $5.59, which included the significant benefit from the Beauty Brands transaction that was completed in October 2016.

$PG {{ '2018-01-23T13:58:56+0000' | timeago}} • Announcement

$PG maintained its organic sales growth estimate of 2-3% for FY18. The company estimates all-in sales growth of about 3% for FY18, which includes a neutral to half-a-percentage-point benefit to sales growth from the combined impacts of acquisitions and divestitures and foreign exchange.

$PG {{ '2018-01-23T13:58:44+0000' | timeago}} • Announcement

$PG's net sales for 2Q18 rose 3% year-over-year. This includes a 1% positive impact from foreign exchange. Organic sales and volume both increased 2%. A 1% positive mix impact from the disproportionate growth of higher priced categories, Skin & Personal Care and Personal Health Care, was offset by a negative pricing impact of 1%.

$PG {{ '2018-01-23T13:58:27+0000' | timeago}} • Announcement

$PG reported a 68% drop in 2Q18 earnings due to the Beauty Brands divestiture gain in the base period and the latest quarter net income tax charge related to the recent U.S. Tax Cuts and Jobs Act. Net income fell to $2.5Bil or $0.93 per share from $7.88Bil or $2.88 per share last year. Net sales rose 3% to $17.4Bil. Core EPS increased 10% to $1.19.

$PG {{ '2018-01-23T13:50:51+0000' | timeago}} • Infographic

$PG Procter & Gamble Co. Earnings AlphaGraphic: Q2 2018 Highlights

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$HUBB {{ '2017-12-26T16:55:15+0000' | timeago}} • Announcement

An affiliate of Sun Capital Partners Inc. agreed to sell Aclara Technologies LLC, a global provider of smart infrastructure solutions for utilities, to $HUBB's subsidiary Hubbell Power Systems Inc. for $1.1Bil. Aclara is established as successful independent business through new capital investment and strategic acquisitions.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

Recent Transcripts

PG (The Procter & Gamble Company)
Tuesday, January 23 2018 - 1:30pm
BF.B (Brown-Forman Corporation)
Wednesday, December 6 2017 - 3:00pm
NOMD (Nomad Foods Limited)
Tuesday, November 28 2017 - 1:30pm
CGNT (Cogentix Medical, Inc.)
Tuesday, November 7 2017 - 9:30pm
GCP (GCP Applied Technologies Inc.)
Thursday, November 2 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
OSB (Norbord, Inc.)
Friday, October 27 2017 - 3:00pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm
HUBB (Hubbell Inc.)
Tuesday, October 24 2017 - 2:00pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
NOMD (Nomad Foods Limited)
Thursday, August 24 2017 - 12:30pm
GCP (GCP Applied Technologies Inc.)
Thursday, August 3 2017 - 2:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
CGNT (Cogentix Medical, Inc.)
Tuesday, August 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
OSB (Norbord, Inc.)
Friday, July 28 2017 - 3:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm

AlphaGraphics you may like